Christopher Green, MD
Internal Medicine · Memphis, TNNPI 1700897774
Payments from drug & device makers
Across 507 payments — averaging $17.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$1K
- AbbVie$1K
- Lilly USA, LLC$562
- Sanofi-aventis U.S. LLC$556
- Abbott$435
- plus $3K from 25 others
What the payments were for
- Food & beverage$8,659100%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 101 | $1,760 |
| Novo Nordisk | 70 | $1,278 |
| AbbVie(2 entities) | 49 | $1,002 |
| Lilly USA, LLC | 36 | $562 |
| Sanofi-aventis U.S. LLC | 35 | $556 |
| Abbott | 22 | $435 |
| Bayer | 26 | $435 |
| Amarin Pharma, Inc. | 24 | $425 |
| Merck | 27 | $373 |
| Boehringer Ingelheim | 23 | $347 |
| Johnson & Johnson | 18 | $274 |
| Amgen | 11 | $190 |
| Eisai Inc. | 11 | $170 |
| Pfizer | 10 | $167 |
| GSK | 7 | $121 |
| Astellas Pharma US Inc | 5 | $94 |
| Dexcom, Inc. | 5 | $79 |
| Endo Pharmaceuticals Inc. | 5 | $68 |
| Exact Sciences | 4 | $64 |
| Sunovion Pharmaceuticals Inc. | 4 | $59 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $46 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Genentech USA, Inc. | 1 | $20 |
| Medtronic | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Ascensia Diabetes Care US Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Hikma Pharmaceuticals USA | 1 | $11 |
How this compares
$8,685 in reported general payments places this provider in the 90th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 56 | $54,803 |
| JardianceEmpagliflozin | 45 | $44,828 |
| FarxigaDapagliflozin Propanediol | 57 | $43,509 |
| JanuviaSitagliptin Phosphate | 43 | $43,431 |
| OzempicSemaglutide | 34 | $37,871 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $25,951 |
| JanumetSitagliptin Phos/Metformin Hcl | 28 | $21,361 |
| MounjaroTirzepatide | 15 | $14,705 |
| TradjentaLinagliptin | 16 | $11,041 |
| SynjardyEmpagliflozin/Metformin Hcl | 12 | $10,405 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,673 |
| Atorvastatin Calcium | 329 | $4,205 |
| Potassium Chloride | 139 | $3,620 |
| Amlodipine Besylate | 544 | $3,284 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $2,985 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $347 | $66,27473 claims |
| MerckJanuvia, Janumet | $373 | $64,79371 claims |
| PfizerEliquis | $167 | $54,80356 claims |
| AstraZenecaFarxiga | $1,760 | $43,50957 claims |
| Novo NordiskOzempic | $1,278 | $37,87134 claims |
| Lilly USA, LLCMounjaro | $562 | $14,70515 claims |
| GSKBreo Ellipta | $121 | $4,67312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Memphis
- Phillip NorthcrossMemphis$39K
- Lawrence WhitlockMemphis$36K
- Angela WatsonMemphis$32K
- William CushmanMemphis$24K
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.